Nuclear Therapy

Nuclear Therapy
Advanced Radionuclide Therapies
Radionuclide Therapies are fast gaining an important position in the management of several malignancies.
Mahatma Gandhi Cancer Hospital & Research Institute is glad to announce the initiation of Radionuclide Therapy facility, for the first time in the state of Andhra Pradesh.

Advantages of Nuclear Therapy:
  • Very specific target binding of the pharmaceuticals
  • Delivering large doses of radiation to the target tissue
  • Very minimal radiation to the normal tissues
  • Very minimal side-effect profile
  • Significant improvement in quality of life and survival of patients
Following Radionuclide Therapies are available for Cancer Related problems:
131 Iodine High Dose Therapy:

Iodine-131 Therapy is an established modality for management of Thyroid Cancer. It has been used for well differentiated Thyroid Carcinoma both Papillary and Follicular types for

  • Remnant Ablation,
  • Ablation of Lymphnodal or Local Residual Disease
  • Adjuvant treatment of Distant Metastases
177 Lutetium DOTATATE Therapy:
This is an advanced therapy that is only recently made available in the US. DOTATE is a Somatostatin Receptor Analogue. Somatostatin Receptors are over-expressed in most tumors of Neuro-endocrine origin. Conventionally Metastatic Neuroendoctine Tumors are very resistant to Chemotherapy and Radiotherapy. 177Lu – DOTATATE (LuTaTe) Therapy significantly improves outcomes in patients with Progressive Metastatic Neuroendocrine tumors. This therapy can be used in

  • Metastatic Carcinoid and Neuroendocrine Tumors
  • Metastatic Pheochromocytoma and Paraganglioma
  • Metastatic Neuroblastoma
  • Inoperable Meningiomas
177 Lutetium PSMA Therapy:

Prostate Specific Membrane Antigen (PSMA) is a Type || Transmembrane Protein expressed on cell surface and normally found in prostate gland, jejunum, salivary glands and kidneys. It is over expressed in Adeno Carcinoma of the Prostate.
Targeted Therapy with 177 Lu PSMA is effective in controlling Metastatic Hormone Resistant Prostate Carcinoma.

Radionuclide Therapy of Hepatocellular Carcinoma:

In patients with inoperable Hepatocellular Carcinoma including those with Portal Vein Thrombosis, Radionuclide Therapy with

  • Labeled Lipiodal (131 Iodine or 188 Rhenium)
  • Labeled Glass/Resin Bead Particles (Yttrium 90)
Significantly increase the survival of the patients with minimal side effects. Radionuclide Therapy with Lipiodal can also be used as an Adjuvant Therapy after surgical resection of HCC to reduce recurrences.
Palliation of bone pain from Metastases:

Palliation of intractable pain from Metastatic Disease in patients with Osteoblastic Metastases such as Breast Cancer or Prostate cancer can be effectively done with intravenous injection of Radionuclides such as 153Samarium-EDTMP or Phosphorus-32.

Treatment of Benign Diseases:

Grave’s Disease / Autonomous Functioning Thyroid Nodule:

  • 131-Iodine is a very effective treatment for Grave’s disease and AFTN and reducing size of Multi Nodular Goiter prior to surgery
Radiosynovectomy for Inflammatory Joint Diseases:

  • Injection of Radionulides into the joints results in slowing down of disease progression and drastic improvement of pain in patients with Inflammatory Arthritis and is indicated in
  • Refractory Painful Inflammatory Arthritis such as Rheumatoid Arthritis and other Spondyloarthritidis
  • Hemophilic Arthritis
  • Pigmented Villinodular Synovitis
  • Persistent Effusion after Joint Prosthesis
  • Undifferentiated Arthritis (where the Arthritis is characterized by Synovitis, Synovial Thickening or Effusion)